CRISPR mediated Transcription Factor DBD Knockout Screening Service
Introduction
Creative Biolabs' Custom CRISPR mediated Transcription Factor (TF) DBD Knockout Screening Service uses Saturating Functional Genomics and Multi-Modal Epigenetic Readout to systematically identify TFs regulating biological phenotypes. Targeting TFs' DBD ensures functional null phenotypes, linking regulatory genes to downstream effects. Backed by functional genomics insights, it de-risks candidates, uncovers high-leverage regulatory hubs, and solves complex pathway regulation challenges to accelerate R&D with potent therapeutic targets.
Discover How We Can Help - Request a Consultation
CRISPR mediated Transcription Factor DBD Knockout Screening Service
Background of Transcription Factor DBD Knockout
Transcription Factors (TFs) exert control by binding to specific DNA sequences via their DNA Binding Domain (DBD) to either promote or repress gene transcription. Traditional gene-level knockout screens can sometimes miss TFs with redundant roles or complex regulatory inputs. By specifically targeting the DBD—the functional core required for sequence-specific regulation—our approach creates a clear loss-of-function phenotype, isolating TFs that are non-redundantly essential for the observed biological state.
Screening Purpose
The primary purpose of the CRISPR mediated Transcription Factor DBD Knockout Screening Service is to address the gap in knowledge between gene sequence and biological function. Specifically:
- To identify novel, high-value regulatory targets that are not part of the direct enzymatic machinery but control the entire pathway's stability or kinetics.
- To systematically deconvolute complex regulatory networks involving transcriptional initiation, chromatin state, and non-coding RNA mechanisms.
- To provide an unbiased, saturating search for master regulators that can be targeted to maximize therapeutic effect or optimize cell line performance.
Subsequent Application
The high-confidence targets identified through our DBD knockout screen have broad and transformative applications, including:
- Drug Target Validation and Discovery: Identifying novel TFs (e.g., those controlling disease-relevant genes or immune checkpoints) for small molecule or gene therapy development.
- Cell Line and Bio-Production Optimization: Engineering cell lines for enhanced production of biologics by knocking out transcriptional repressors or activating key expression TFs.
- Gene Therapy Development: Pinpointing the most critical host factors required for viral persistence (e.g., HIV latency) or host-pathogen interactions.
Workflow
Our service follows a rigorous, phased workflow, providing clear milestones and expected outcomes at every stage.
Required Starting Materials
- Target Pathway/Phenotype Definition: Clear description of the biological process to be screened (e.g., viral latency reversal, cell differentiation, or a specific PTM biosynthesis pathway).
- Cell Line/Model System: Well-characterized cell line (e.g., stable Cas9-expressing line, primary cells, or patient-derived cells) suitable for high-throughput screening.
- Functional Reporter System: A robust, quantifiable functional assay (e.g., fluorescent reporter, viability assay, metabolic label readout) linked to the target phenotype.
DBD Library Design and Construction
We leverage proprietary algorithms to design a saturating, high-coverage lentiviral gRNA library specifically targeting the DNA Binding Domains of thousands of TFs. The outcome is a high-titer, custom-validated library ready for transduction.
Genome-Wide Functional Screen
The library is transduced into the client's cell model at a low multiplicity of infection (MOI). Cells are subjected to the defined functional selection pressure (e.g., toxin, drug, or stimulus) to enrich for cells where TF knockout has altered the target phenotype.
Deep Sequencing and Bioinformatic Analysis
Genomic DNA is extracted from the enriched and control populations. Next-generation sequencing is performed on the gRNA cassette. Our specialized pipeline uses advanced computational tools to calculate the Log2-Fold Change (LFC), identifying the highest-confidence regulatory hits.
Target Validation and MoA Characterization
Top TF candidates are individually validated using independent single-gRNAs. This phase includes advanced assays such as ChIP-qPCR for chromatin occupancy (e.g., RNAPII recruitment, H3K9me3 status) and lncRNA profiling to confirm multi-modal regulatory mechanisms.
Data Delivery and Consultative Reporting
We provide a comprehensive, interpretation-ready report and a dedicated consultation with our expert scientists to translate raw data into actionable therapeutic strategies.
Final Deliverables
- High-Confidence Target Report: A ranked list of validated, non-redundant Transcription Factor DBD targets, complete with LFC scores and statistical significance.
- Mechanistic Validation Data Package: Comprehensive data showing the validated TF's effect on pathway kinetics, gene expression, and multi-modal regulation (e.g., ChIP and lncRNA data).
- Lead Candidate Recommendation: Strategic recommendations on how to proceed with the identified regulatory hubs for therapeutic development or cell line engineering.
Estimated Timeframe
The typical timeframe for this comprehensive service ranges from 10 to 16 weeks, depending on the complexity of the cell model, the stringency of the functional readout, and the depth of the requested validation package.
What We Can Offer
Creative Biolabs is committed to providing a flexible, high-quality, and scientifically rigorous screening experience tailored precisely to your therapeutic needs. Our service is not a fixed menu; it is a customizable partnership built for high-impact discovery.
Custom DBD Library Design and Validation
We optimize the gRNA design exclusively for the DNA Binding Domain (DBD) of TFs relevant to your specific biological question, guaranteeing the highest functional signal-to-noise ratio.
Flexible Functional Screening Modes
We run the screening process in batch, fed-batch, or continuous selection modes, adapting the selection pressure and duration to capture subtle regulatory phenotypes and kinetic-dependent effects.
Integrated Multi-Modal Readout
Our proprietary process allows for the seamless addition of follow-up assays (e.g., ChIP-qPCR, RT-qPCR for lncRNA stability, and western blot), connecting the genetic hit directly to the epigenetic or non-coding RNA mechanism.
Proprietary, High-Stringency Bioinformatics
Utilizing advanced statistical pipelines, we provide deep sequencing analysis that effectively manages noise and delivers highly validated Log2-Fold Change (LFC) data for the most significant regulatory hits.
One-on-One Expert Consultation
Throughout your project, you receive dedicated support from our senior scientific team, ensuring the initial design is optimized and the final data is translated into actionable therapeutic strategies.
Scalable Throughput and Quality Assurance
We maintain a well-established quality system throughout the screening process, capable of supporting projects from initial proof-of-concept to large-scale, high-throughput target validation.
Experience the Creative Biolabs Advantage - Get a Quote Today
Customer Reviews
FAQs
How does the DBD Knockout Screen compare to a standard whole-gene knockout screen for TFs?
The DBD knockout approach is significantly more precise. While a standard knockout targets the entire gene, our method specifically disrupts the DNA-binding function, delivering a cleaner readout directly tied to the TF's regulatory role. This eliminates false positives from non-specific gene disruption and provides higher-confidence functional hits, especially for TFs with complex or redundant domains.
Can your service be used to find regulators of non-coding RNA, like lncRNAs?
Absolutely. Our approach discovers upstream regulators (TFs like ATF1) that modulate downstream elements, including lncRNA transcription and stability. By screening for a functional phenotype and validating the hit's mechanism, we map the entire regulatory axis: TF → lncRNA → mRNA stability → Protein expression.
What is the typical stringency, and will the screen miss TFs with redundant functions?
We use saturating library coverage (≥300×) and stringent functional selection to maximize success. While we prioritize non-redundant, high-impact regulators (valuable drug targets), our high coverage and specialized bioinformatics detect even subtle cooperative effects. Customized validation strategies are available upon request.
What types of validation are included to confirm the mechanism of a high-confidence hit?
Beyond simple gene confirmation, standard validation includes functional re-testing with single-gRNAs and advanced assays like ChIP-qPCR. These measure the TF's impact on chromatin markers (e.g., H3K9me3) and RNAPII recruitment, confirming the precise epigenetic and transcriptional MoA for direct progression to lead optimization.
My target pathway requires rapid kinetic control. Is your screen sensitive enough to capture these time-sensitive regulators?
Yes. Our methodology leverages the principle that biological success often depends on regulatory response rapidity (the IRF2-like effect). We customize the functional selection window to capture kinetic regulators. For rapid processes (e.g., short stimulation windows), we design reporters and sorting strategies to isolate cells where TF knockout compromises time-sensitive responses.
Creative Biolabs is your expert partner in functional genomics, specializing in the identification of critical Transcription Factor regulatory hubs. Our CRISPR mediated Transcription Factor DBD Knockout Screening Service delivers saturating coverage, kinetic insights, and multi-modal mechanism-of-action data, transforming your most complex biological challenges into actionable therapeutic leads.
Our Team for More Information and to Discuss Your Project
